To test this hypothesis, we focus on breast tumors, since we have previously demonstrated that in mammary carcinomas, GSDMB over-expression has prognostic value and promotes multiple pro-tumor effects in vitro and in vivo [39, 41, 42, 48]. The gene discussed is GSDMB; the disease is breast neoplasm.